Pharmacokinetics of pyrazinamide and its metabolites in patients with hepatic cirrhotic insufficiency.
Identifieur interne : 000441 ( PubMed/Curation ); précédent : 000440; suivant : 000442Pharmacokinetics of pyrazinamide and its metabolites in patients with hepatic cirrhotic insufficiency.
Auteurs : C. Lacroix [France] ; J L Tranvouez ; T. Phan Hoang ; H. Duwoos ; O. LafontSource :
- Arzneimittel-Forschung [ 0004-4172 ] ; 1990.
English descriptors
- KwdEn :
- MESH :
- chemical , analogs & derivatives : Pyrazinamide.
- chemical , blood : Pyrazinamide.
- metabolism : Liver Cirrhosis, Pyrazinamide.
- chemical , pharmacokinetics : Pyrazinamide.
- Adult, Chromatography, High Pressure Liquid, Female, Half-Life, Humans, Liver Function Tests, Male.
Abstract
The pharmacokinetics of pyrazinamide (Pirilène) and its metabolites are evaluated in ten subjects with hepatic insufficiency, after an oral dose of 19.3 +/- 0.6 mg.kg-1 and the results are compared to those of a group of nine healthy subjects (control group). The results exhibit a marked reduction of the pyrazinamide total clearance (0.48 vs 0.84 ml.min-1.kg-1) and an increase in half-life from 9.19 h to 15.07 h in the patients group. The area under the curve of pyrazinoic acid (the main metabolite) is increased from 97 to 280 mg.h.l-1 with a half-life twice as much as that of the control group. The hepatic insufficiency entails a marked reduction of the common posology as well as a closer survey of the biologic hepatic parameters and of uric acid the renal elimination of which is inhibited by pyrazinoic acid.
PubMed: 2340003
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000441
Links to Exploration step
pubmed:2340003Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pharmacokinetics of pyrazinamide and its metabolites in patients with hepatic cirrhotic insufficiency.</title><author><name sortKey="Lacroix, C" sort="Lacroix, C" uniqKey="Lacroix C" first="C" last="Lacroix">C. Lacroix</name><affiliation wicri:level="1"><nlm:affiliation>Unité de Pharmacocinétique, Centre Hospitalier Général, Le Havre, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Unité de Pharmacocinétique, Centre Hospitalier Général, Le Havre</wicri:regionArea></affiliation></author><author><name sortKey="Tranvouez, J L" sort="Tranvouez, J L" uniqKey="Tranvouez J" first="J L" last="Tranvouez">J L Tranvouez</name></author><author><name sortKey="Phan Hoang, T" sort="Phan Hoang, T" uniqKey="Phan Hoang T" first="T" last="Phan Hoang">T. Phan Hoang</name></author><author><name sortKey="Duwoos, H" sort="Duwoos, H" uniqKey="Duwoos H" first="H" last="Duwoos">H. Duwoos</name></author><author><name sortKey="Lafont, O" sort="Lafont, O" uniqKey="Lafont O" first="O" last="Lafont">O. Lafont</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1990">1990</date><idno type="RBID">pubmed:2340003</idno><idno type="pmid">2340003</idno><idno type="wicri:Area/PubMed/Corpus">000441</idno><idno type="wicri:Area/PubMed/Curation">000441</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Pharmacokinetics of pyrazinamide and its metabolites in patients with hepatic cirrhotic insufficiency.</title><author><name sortKey="Lacroix, C" sort="Lacroix, C" uniqKey="Lacroix C" first="C" last="Lacroix">C. Lacroix</name><affiliation wicri:level="1"><nlm:affiliation>Unité de Pharmacocinétique, Centre Hospitalier Général, Le Havre, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Unité de Pharmacocinétique, Centre Hospitalier Général, Le Havre</wicri:regionArea></affiliation></author><author><name sortKey="Tranvouez, J L" sort="Tranvouez, J L" uniqKey="Tranvouez J" first="J L" last="Tranvouez">J L Tranvouez</name></author><author><name sortKey="Phan Hoang, T" sort="Phan Hoang, T" uniqKey="Phan Hoang T" first="T" last="Phan Hoang">T. Phan Hoang</name></author><author><name sortKey="Duwoos, H" sort="Duwoos, H" uniqKey="Duwoos H" first="H" last="Duwoos">H. Duwoos</name></author><author><name sortKey="Lafont, O" sort="Lafont, O" uniqKey="Lafont O" first="O" last="Lafont">O. Lafont</name></author></analytic><series><title level="j">Arzneimittel-Forschung</title><idno type="ISSN">0004-4172</idno><imprint><date when="1990" type="published">1990</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Chromatography, High Pressure Liquid</term><term>Female</term><term>Half-Life</term><term>Humans</term><term>Liver Cirrhosis (metabolism)</term><term>Liver Function Tests</term><term>Male</term><term>Pyrazinamide (analogs & derivatives)</term><term>Pyrazinamide (blood)</term><term>Pyrazinamide (metabolism)</term><term>Pyrazinamide (pharmacokinetics)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Pyrazinamide</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Pyrazinamide</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Liver Cirrhosis</term><term>Pyrazinamide</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Pyrazinamide</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Chromatography, High Pressure Liquid</term><term>Female</term><term>Half-Life</term><term>Humans</term><term>Liver Function Tests</term><term>Male</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The pharmacokinetics of pyrazinamide (Pirilène) and its metabolites are evaluated in ten subjects with hepatic insufficiency, after an oral dose of 19.3 +/- 0.6 mg.kg-1 and the results are compared to those of a group of nine healthy subjects (control group). The results exhibit a marked reduction of the pyrazinamide total clearance (0.48 vs 0.84 ml.min-1.kg-1) and an increase in half-life from 9.19 h to 15.07 h in the patients group. The area under the curve of pyrazinoic acid (the main metabolite) is increased from 97 to 280 mg.h.l-1 with a half-life twice as much as that of the control group. The hepatic insufficiency entails a marked reduction of the common posology as well as a closer survey of the biologic hepatic parameters and of uric acid the renal elimination of which is inhibited by pyrazinoic acid.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2340003</PMID><DateCreated><Year>1990</Year><Month>6</Month><Day>20</Day></DateCreated><DateCompleted><Year>1990</Year><Month>06</Month><Day>20</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0004-4172</ISSN><JournalIssue CitedMedium="Print"><Volume>40</Volume><Issue>1</Issue><PubDate><Year>1990</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Arzneimittel-Forschung</Title><ISOAbbreviation>Arzneimittelforschung</ISOAbbreviation></Journal><ArticleTitle>Pharmacokinetics of pyrazinamide and its metabolites in patients with hepatic cirrhotic insufficiency.</ArticleTitle><Pagination><MedlinePgn>76-9</MedlinePgn></Pagination><Abstract><AbstractText>The pharmacokinetics of pyrazinamide (Pirilène) and its metabolites are evaluated in ten subjects with hepatic insufficiency, after an oral dose of 19.3 +/- 0.6 mg.kg-1 and the results are compared to those of a group of nine healthy subjects (control group). The results exhibit a marked reduction of the pyrazinamide total clearance (0.48 vs 0.84 ml.min-1.kg-1) and an increase in half-life from 9.19 h to 15.07 h in the patients group. The area under the curve of pyrazinoic acid (the main metabolite) is increased from 97 to 280 mg.h.l-1 with a half-life twice as much as that of the control group. The hepatic insufficiency entails a marked reduction of the common posology as well as a closer survey of the biologic hepatic parameters and of uric acid the renal elimination of which is inhibited by pyrazinoic acid.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lacroix</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Unité de Pharmacocinétique, Centre Hospitalier Général, Le Havre, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tranvouez</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Phan Hoang</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Duwoos</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Lafont</LastName><ForeName>O</ForeName><Initials>O</Initials></Author></AuthorList><Language>ENG</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Arzneimittelforschung</MedlineTA><NlmUniqueID>0372660</NlmUniqueID><ISSNLinking>0004-4172</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>13924-96-4</RegistryNumber><NameOfSubstance UI="C032191">5-hydroxypyrazinamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>2KNI5N06TI</RegistryNumber><NameOfSubstance UI="D011718">Pyrazinamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>2WB23298SP</RegistryNumber><NameOfSubstance UI="C005296">pyrazinoic acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>34604-60-9</RegistryNumber><NameOfSubstance UI="C054996">5-hydroxypyrazinoic acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002851" MajorTopicYN="N">Chromatography, High Pressure Liquid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006207" MajorTopicYN="N">Half-Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008111" MajorTopicYN="N">Liver Function Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011718" MajorTopicYN="N">Pyrazinamide</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2340003</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/France/explor/LeHavreV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000441 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000441 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/France
|area= LeHavreV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:2340003
|texte= Pharmacokinetics of pyrazinamide and its metabolites in patients with hepatic cirrhotic insufficiency.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:2340003" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LeHavreV1
| This area was generated with Dilib version V0.6.25. |  |